Menu

Studies Retracted After UCLA Investigation

Most of the authors have had papers pulled in the past.

Jul 21, 2017
Diana Kwon

PIXABAY, JACKMAC34A 2011 Cancer Research paper was retracted earlier this month (July 2) after an investigation by the University of California, Los Angeles (UCLA). The work was conducted by a group of cancer investigators at the university, including James Economou, the former vice chancellor for research.

According to the retraction report, the request came from UCLA, where an institutional review found that one of the paper’s figures duplicated aspects of another paper.

“This is the second retraction we’re aware of to come out of an investigation by UCLA’s Office of Research Policy and Compliance that has touched this group of scientists,” Retraction Watch reports. A 2012 Molecular Cancer Therapeutics paper coauthored by Economou was retracted in May.

This is the fourth retraction for one of the study’s coauthors, Benjamin Bonavida, a retired UCLA scientist. When asked about the most recent Cancer Research study, he tells Retraction Watch that “all the work was done in Economou’s lab, not mine. I have no idea what exactly took place.”

Only one of the coauthors of the Cancer Research paper has no previous retractions.

Retractions of scientific papers are on the rise. Just last year, more than 650 papers were pulled for various reasons, ranging from image duplication to fraud.

See “Infographic: Web of Retractions

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.